Waldenström’s Macroglobulinemia Associated With AA Amyloidosis

  • J. Gardyn
  • A. Schwartz
  • R. Gal
  • U. Lewinski
  • D. Kristt
  • A. M. Cohen
Case Report


It is widely accepted that amyloidosis in Waldenström’s macroglobulinemia (WM) is exclusively due to amyloid light-chain deposition. However, only a small number of previous reports have actually characterized the type of amyloid in WM.We now report the third patient with WM and amyloid A protein (AA) amyloidosis. This patient developed malabsorption, nephrotic syndrome, and orthostatic hypotension. AA was immunohistochemically demonstrated in the rectal biopsy. In conjunction with previous examples of AA amyloidosis, the present report raises the possibility that AA amyloidosis may also occur in WM patients.

Key words

Secondary amyloidosis Waldenström’s macroglobulinemia Nephrotic syndrome 


  1. 1.
    Dimopoulos MA, Alexanian R. Waldenström’s macroglobulinemia.Blood. 1994;83:1452–1459.PubMedGoogle Scholar
  2. 2.
    Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments.Br J Haematol. 1997;99:245–256.PubMedCrossRefGoogle Scholar
  3. 3.
    Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium.J Histochem Cytochem. 1998;46:1377–1384.PubMedGoogle Scholar
  4. 4.
    Orfila C, Rakotoarivony J, Segonds A, Suc JM. Immunofluorescence study of “non-idiopathic” renal amyloidosis.Hum Pathol. 1983;14:362–367.PubMedCrossRefGoogle Scholar
  5. 5.
    Hirose H, Takemura Y, Honma S, et al. Nephrotic syndrome associated with generalized amyloidosis and IgM-monoclonal proteinemia.Jpn J Med. 1991;30:130–134.PubMedGoogle Scholar
  6. 6.
    Faa G, Van Eyken P, De Vos R, et al. Light chain deposition disease of the liver associated with AL-type amyloidosis and severe cholestasis.J Hepatol. 1991;12:75–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Julien J, Vital C, Vallat JM, et al. IgM demyelinative neuropathy with amyloidosis and biclonal gammopathy.Ann Neurol. 1984;15:395–399.PubMedCrossRefGoogle Scholar
  8. 8.
    Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström’s macroglobulinemia.J Clin Oncol. 1993;11:914–920.PubMedGoogle Scholar
  9. 9.
    Jones CH, Kanagasundaram NS, Coral AP, Coyne JD, Will EJ. Combined Waldenstrom’s macroglobulinaemia associated AL and beta-2-microglobulin amyloidosis.Nephrol Dial Transplant. 1997;12:2708–2712.PubMedCrossRefGoogle Scholar
  10. 10.
    Zatloukal P, Bezdicek P, Schimonova M, Havlicek F, Tesarova P, Slovakova A. Waldenstrom’s macroglobulinemia with pulmonary amyloidosis.Respiration. 1998;65:414–416.PubMedCrossRefGoogle Scholar
  11. 11.
    Strege RJ, Saeger W, Linke RP. Diagnosis and immunohistochemical classification of systemic amyloidoses. Report of 43 cases in an unselected autopsy series.Virchows Arch. 1998;433:19–27.PubMedCrossRefGoogle Scholar
  12. 12.
    Møyner K, Sletten K, Husby G, Natvig JB. An unusually large (83 amino acid residues) amyloid fibril protein AA from a patient with Waldenström’s macroglobulinemia and amyloidosis.Scand J Immunol. 1980;11:549–554.PubMedCrossRefGoogle Scholar
  13. 13.
    Ogami Y, Takasugi M, Soejima M. et al. Waldenstrom’s macroglobulinemia associated with amyloidosis and crescentic glomerulonephritis.Nephron. 1989;51:95–98.PubMedCrossRefGoogle Scholar
  14. 14.
    Wright JR, Calkins E, Humphrey RL. Potassium permanganate reaction in amyloidosis. A histologic method to assist in differentiating forms of this disease.Lab Invest. 1977;36:274–281.PubMedGoogle Scholar
  15. 15.
    Ordi J, Grau JM, Junque A, Nomdedeu B, Palacin A, Cardesa A. Secondary (AA) amyloidosis associated with Castleman’s disease.Am J Clin Path. 1993;100:394–397.PubMedGoogle Scholar
  16. 16.
    Ikeda S, Chisuwa H, Kawasaki S, et al. Systemic reactive amyloidosis associated with Castleman’s disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.J Clin Pathol. 1997;50:965–967.PubMedCrossRefGoogle Scholar
  17. 17.
    Husby G. Treatment of amyloidosis and the rheumatologist. State of the art and perspectives for the future.Scand J Rheumatol. 1998;7:161–165.CrossRefGoogle Scholar
  18. 18.
    Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.Nature Med. 2000;6:643–651.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  • J. Gardyn
    • 1
  • A. Schwartz
    • 2
  • R. Gal
    • 2
  • U. Lewinski
    • 1
  • D. Kristt
    • 2
  • A. M. Cohen
    • 1
  1. 1.Hematology UnitPathology Institute, Golda-Hasharon Campus, Rabin Medical Center and Sackler School of Medicine, Tel-Aviv UniversityPetah-TikvaIsrael
  2. 2.Pathology Institute, Golda-Hasharon Campus, Rabin Medical Center and Sackler School of Medicine, Tel-Aviv UniversityPetah-TikvaIsrael

Personalised recommendations